Comparative Pharmacology
Head-to-head clinical analysis: DHIVY versus NORETHIN 1 35E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DHIVY versus NORETHIN 1 35E 21.
DHIVY vs NORETHIN 1/35E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release from pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial lining.
DHIVY is not a recognized drug. No dosing information available.
1 tablet orally once daily for 21 days, followed by 7 days off, then repeat. Each tablet contains 1 mg norethindrone acetate and 0.035 mg ethinyl estradiol.
None Documented
None Documented
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when CrCl <30 mL/min).
Norethindrone: terminal half-life ~7-8 hours (range 5-12 h). Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 h). The half-life supports once-daily dosing with stable serum concentrations achieved after 3-5 days.
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Norethindrone and ethinyl estradiol are primarily excreted via urine (approximately 60-80% as metabolites) and feces (about 10-30%). Renal excretion accounts for the majority, with biliary/fecal elimination contributing a minor but significant fraction.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive